We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MC:EURONEXT PARISLVMH Moet Hennessy Louis Vuitton SE Analysis

Data as of 2026-05-19 - not real-time

$63.16

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Moelis & Company is trading at $63.16, which sits below its 20‑day SMA of $65.27 and the 200‑day SMA of $67.01, indicating short‑term weakness, while remaining just above the 50‑day SMA of $61.08. Technical signals are mixed: the MACD histogram is negative and the MACD line trails its signal, the RSI sits at 46 (neutral), and volume has been trending down, all pointing to a cautious near‑term outlook. The latest earnings missed expectations, with adjusted EPS of $0.50 versus the consensus $0.59 and a 21.9% decline in net profit YoY, which pressured the stock despite a modest 4.3% revenue increase. Fundamentally, the firm remains strong with a gross margin of 92.3%, operating margin of 12.7%, and an impressive ROE of 41.8%, but its forward P/E of 15.98 suggests a more reasonable valuation than the current trailing P/E of 22.7, which is above the industry average of 16.6. The DCF‑derived fair value of $66.48 provides roughly a 12% upside, aligning with analyst median targets around $70, while the dividend yield of 4.07% is attractive but the payout ratio of 93.5% raises sustainability concerns. Overall, the market is in an "Extreme Greed" phase (Fear & Greed Index 89.45), but high beta (≈1.6) and 30‑day volatility of 34% underscore significant risk as the stock navigates near its support at $61.85 and faces resistance near $71.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Q1 earnings miss and lower EPS than consensus
  • Bearish MACD and decreasing volume
  • High dividend yield but near‑full payout ratio

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value indicates ~12% upside
  • Strong ROE and high gross margins
  • Forward P/E compression toward industry norms

Long Term

> 3 years
Neutral
Model confidence: 8/10

Key Factors

  • Sustainable advisory franchise with global reach
  • Consistently high profitability metrics
  • Dividend attractiveness tempered by payout sustainability concerns

Key Metrics & Analysis

Financial Health

Revenue Growth4.30%
Profit Margin14.46%
P/E Ratio22.7
ROE41.77%
ROA19.89%
Debt/Equity42.94
P/B Ratio9.6
Op. Cash Flow$463.0M
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI46.1
Support$61.85
Resistance$70.97
MA 20$65.27
MA 50$61.08
MA 200$67.01
MACDBearish
VolumeDecreasing
Fear & Greed Index89.45

Valuation

Fair Value$66.48
Target Price$71.00
Upside/Downside12.42%
GradeUndervalued
TypeBlend
Dividend Yield4.07%

Risk Assessment

Beta1.61
Volatility34.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.